[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rhinovirus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rhinovirus":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,143],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100619281","the-rhinovirus-hospitalization-and-investigation-of-nasal-airway-omics-rhino-study-100619281",false,"NCT07342582","The Rhinovirus Hospitalization and Investigation of Nasal-airway Omics (RHINO) Study","Identifying the Burden of Hospitalization Due to Rhinovirus (RV) in Children and Mechanisms of Pathogenesis Using Airway Molecular Profiling","Inclusion Criteria (Aim 1 and Aim 2b Community Groups):\n\n* Parent\u002Flegal guardian is willing and able to provide informed consent in English.\n* Willing to comply with all study procedures and be available for the duration of the study.\n* Younger Community Group: Generally healthy children 12 to 36 months of age at the time of enrollment\n* Older Community Group: Generally healthy children 5 to 17 years of age at the time of enrollment.\n* Current patient within primary care system at UW Health\n\nInclusion Criteria (Aim 2a: Hospitalized Group):\n\n* Parent\u002Flegal guardian is willing and able to provide informed consent in English.\n* Admitted to American Family Children's Hospital (AFCH) within the past 24 hours\n* Children under 18 years of age at the time of enrollment\n* Has a diagnosis of bronchiolitis, asthma exacerbation or CAP OR is an infant less than 6 months of age with fever greater than 38 degrees Celsius within 24 hours of hospital admission\n\nExclusion Criteria (all participants):\n\n* Congenital or currently acquired immunosuppressive condition or medications (e.g., congenital immunodeficiency, Leukemia, Lupus)\n* Congenital anomalies that might alter frequency of infection (e.g., unrepaired cleft palate, bronchial cyst, pulmonary sequestration)\n* Presence of tracheostomy or gastrostomy tube\n* Previously enrolled a different group in the study\n* Other child in the same household already enrolled in the study\n* Not suitable for study participation due to other reasons at the discretion of the investigators.\n\nExclusion Criteria (Aim 1: Community Group Only):\n\n* History of chronic pulmonary diseases (e.g., asthma, cystic fibrosis, bronchopulmonary dysplasia (BPD)) (Note: asthma IS exclusionary)\n* Acute upper respiratory symptoms within the past week (7 days) at the time of enrollment\n\nExclusion Criteria (Aim 2: Hospitalized Group Only):\n\n* History of chronic pulmonary diseases, excluding asthma (e.g., cystic fibrosis, bronchopulmonary dysplasia (BPD)) (Note: asthma is NOT exclusionary)\n* A positive test for any virus other than RV within the 48 hours prior to and including admission.\n\nExclusion Criteria (less than 5 years old only (All participants in Aim 1 and some participants in Aim 2a):\n\n* Born prematurely, less than 32 weeks 0 days gestational age",true,"ALL","17 Years",{"count":20,"type":21},670,"ESTIMATED","OBSERVATIONAL","The goal of this study is to determine the burden of Rhinoviruses (RVs) as a cause of acute, severe, respiratory illnesses leading to hospitalization. A community cohort of 120 children between 12 and 36 months of age will be enrolled in the first year of the study and followed (when well and sick) for 36 months to identify the circulating RVs and provide samples to establish a host nasal transcriptome differentiating clinical from subclinical RV infections. A hospitalized cohort of 450 infants and children will be enrolled during years 1 through 3 of the study and followed for the duration of their hospitalization to investigate the findings of the community cohort. An additional 100 healthy children aged 5-17 years will be enrolled for age-match comparison with the older hospitalized cohort.",[25],"Rhinovirus",[27,28,29,30,31],"infants","children","symptomatic","asymptomatic","lower respiratory tract infection","NOT_YET_RECRUITING","2026-02-23",{"date":35,"type":36},"2026-02-24","ACTUAL",{"date":38,"type":21},"2026-05",{"date":40,"type":21},"2030-05",{"name":42,"class":43},"University of Wisconsin, Madison","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":16,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":115,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":44},"100620537","risk-assessment-of-community-spread-of-multiple-endemic-infectious-diseases-in-a-one-health-perspective-100620537","NCT07358910","Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","RACSMEI","Inclusion Criteria:\n\n* Residency in the village for more than 6 months;\n* Age between 2 and 75 years old at the time of inclusion;\n* For adults: provision of written consent;\n* For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;\n\nExclusion Criteria:\n\n* Unable to understand or consent;\n* Under guardianship or deprived of liberty;\n* Medical conditions that impede survey participation;\n* Refusal to participate in the study.","2 Years","75 Years",{"count":55,"type":21},10000,"RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.\n\nRACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.\n\nMathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.",[58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,25,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114],"Dengue","Chikungunya","Zika Virus Infection","Japanese Encephalitis","West Nile Virus","Tick-borne Encephalitis (TBE)","Severe Fever With Thrombocytopenia Syndrome","Nipah Virus Infection","Hantavirus Infections","Hepatitis E","Brucellosis","Q Fever","Leptospirosis","Melioidosis","Influenza A and B","Malaria","Yellow Fever","Mayaro Fever","Usutu Virus Infection","Oropouche Fever","Rift Valley Fever","Arenavirus Infections","Measles","Mumps","Rubella","Human Papilloma Virus (HPV)","Rotavirus Disease","Pertussis","Diphteria","Tetanus","Varicella","Hepatitis A","Norovirus Infections","Enterovirus","Adenovirus","Parvovirus","Respiratory Syncytial Virus (RSV)","Cytomegalovirus","Epstein Barr Virus","Salmonella Typhi","Vibrio Cholerae","Legionella Pneumophila Pneumonia","Mycoplasma","Chlamydia","Lymphatic Filariasis","Toxoplasma Gondii","Giardiasis","Entamoeba Histolytica","Leishmaniasis","Strongyloides Stercoralis Infection","Ascaris Lumbricoides","Trichuris Trichiura","Clonorchis Sinensis","Opisthorchis Viverrini","Schistosomiasis","Streptococcus Pneumoniae","Meningitis",[116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132],"Infectious disease","One Health","Population-based survey","Nationally representative survey","Seroepidemiology","Multiplex serology","Seroprevalence","Vector-borne diseases","Zoonoses","Vaccine-preventable diseases","Neglected tropical diseases","Transmission dynamics","Force of infection","Mathematical modelling","Spatial epidemiology","Precision public health","Cambodia","RECRUITING","2026-01-14",{"date":136,"type":36},"2026-01-22",{"date":138,"type":36},"2025-12-18",{"date":140,"type":21},"2027-09-30",{"name":142,"class":43},"Institut Pasteur du Cambodge",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":151,"phases":152,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":44},"100609673","clinical-validation-of-the-aptitude-medical-systems-metrix-respiratory-panel-test-in-at-homenon-laboratory-settings-100609673","NCT07217639","Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home\u002FNon-Laboratory Settings","Inclusion Criteria:\n\n1. Participant or guardian understands and is able and willing to provide written informed consent, and assent where applicable, prior to study enrollment.\n2. Participant is currently exhibiting signs\u002Fsymptoms of respiratory tract infection including but not limited to fever, cough, sore throat, runny nose, myalgia, headache, chills, new loss of taste or smell, or fatigue. Participant must still be exhibiting symptoms on the day of specimen collection. Days post symptom onset is not to exceed 14 days.\n3. Participant or guardian agrees to read, and is able to read with understanding, the Quick Reference Instructions (QRI) prior to beginning the execution of each of the tests.\n4. Participant or guardian is able and willing to contribute the required swab specimens for testing and understands and is able and willing to sign the study informed consent.\n5. Participant is willing to provide all samples and run tests for the specified investigational devices.\n\nExclusion Criteria:\n\n1. Participant does not understand and\u002For is not able and willing to sign the study informed consent and\u002For assent.\n2. Participant or guardian is not able to comply with nasal swab collection requirements following the Quick Reference Instructions (QRI).\n3. Participant is not currently exhibiting respiratory tract infection symptoms.\n4. Participant has previously participated in the study.\n5. Participant is not able to tolerate specimen collection.\n6. Participant is currently undergoing or has within the past thirty (30) days undergone treatment with prescription medication to treat SARS-CoV-2 infection, including but not limited to Remdesivir (Veklury®), Nirmatrelvir\u002FRitonavir (Paxlovid®), Molnupiravir (LagevrioTM) or receiving convalescent plasma therapy for SARS-CoV- 2.\n7. Participant is currently undergoing or has within the past thirty (30) days undergone an inhaled influenza vaccine (FluMist®), or antiviral treatment, including but not limited to Amantadine (Symmetrel®), Rimantadine (Flumadine®), Zanamivir (Relenza®), Oseltamivir (Tamiflu®), Baloxavir Marboxil (Xofluza®), Amantadine (Symmetrel®), Rimantadine (Flumadine®), or Peramivir (Rapivab®).\n8. Participant is currently undergoing or has within the past thirty (30) days undergone antiviral treatment for RSV, including but not limited to Ribavirin (Virazole®), RSV-IGIV (RespiGam®), Palivizumab (Synagis®), or Nirsevimab-alip (Beyfortus®).\n9. Participants who have had a nasal wash or aspirate as part of their standard of care treatment on day of study visit prior to the study sample collection.\n10. Participants who have had recent craniofacial injury or surgery, including to correct deviation of the nasal septum, within the previous six (6) months.\n11. Participants who do not understand\u002Fread the English language.",{"count":150,"type":21},2000,"INTERVENTIONAL",[153],"NA","The Metrix Respiratory Panel Test will be evaluated for use in Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein. The study will take place in simulated home environments which will be set up within or near active clinical settings (e.g., urgent care facilities). This will be a prospective study conducted at three or more investigational sites located within the United States for the clinical validation of the Metrix Respiratory Panel Test for the detection of SARS-CoV-2, Influenza A, Influenza B, Respiratory syncytial virus, and Rhinovirus in anterior nares (AN) swab samples. Additional sites may be added to the study in order to meet minimum subject\u002Fsample enrollment requirements and geographic prevalence of respiratory virus infections. Comparator testing will be performed to determine the infection status of each sample for comparison to results generated by the candidate test. The primary comparator for the study will be an FDA-cleared assay for the detection of SARS-CoV-2, Influenza A, Influenza B, Respiratory Syncytial Virus, and Rhinovirus.",[156,157,158,159,160,25],"COVID -19","Influenza A","Influenza B","Respiratory Synctial Virus","RSV","2025-10-14",{"date":163,"type":36},"2025-10-16",{"date":165,"type":21},"2025-11-01",{"date":167,"type":21},"2026-09-01",{"name":169,"class":170},"Aptitude Medical Systems","INDUSTRY"]